Member Info for ShareSting

Anyone panicking that SNG001 is only about COVID19 are under researched.

Yes the trials are looking promising, yes we want SNG001 to form part of the treatment plan however it must be noted by investors that this is a multi treatment drug.

We should also remember that there will be a range of drugs used to treat this awful virus. So don’t panic if you read there are other drugs doing well. I believe this is good news in the fight against Covid.

Scout for me the data on the “live” COPD study is very interesting. They also talk about how SNG001 could be extended back in Sept19.

Even without COVID19 , this is a significant game changer IMO.

https://www.synairgen.com/wp-content/uploads/2019/09/190930-Synairgen-Interim-Statement.pdf

Read this.

Some question of the Synairgen team know how the tests are progressing. See the attached statement on the COPD trials, where the board did receive updates :

We conduct a continuous quality control process to check the integrity of the data as it is received. We do this in a blinded fashion i.e. without disclosure of which patients are on placebo and which patients are on active treatment.
Post period-end, as announced in July, a review of the blinded patient symptom data using the Breathlessness Cough and Sputum Score (BCSS score) for the first 40
patients showed that the patients in the trial are being adversely affected by the viruses. A change in the BCSS score of 1 or more is considered to be clinically
1 As we are seeing an average increase in BCSS score of more than 2, there relevant. is clearly an opportunity for inhaled IFN-beta to reduce symptom severity and show clinical benefit

So do the team know ?

This looks very encouraging. Combine the results with the Interferon variants used in other trials and it would seem Interferon could be a strong candidate as go to treatment.

We know Interferon Beta 1a works well against COPD. We also know it is one of the stronger types of Interferon. We also have the patent on delivery.

Well that is a nice way to end the day... although I have no doubt there will be some trying to find the negatives !!

Ghai well said and agreed !

Just one correction. I’m in no hurry for the price to increase. As you and I know, this is not just about Covid19. The agreements being discussed last September will now involve the wider market opportunity. This can take as long as necessary.

Last part (my personal favourite):

The current trial of inhaled IFN-beta paves the way for a Phase IIb trial in COPD patients, and our plan is to partner to be able to conduct this trial. We have an ongoing dialogue with several of the largest pharmaceutical companies who, due to the magnitude of the opportunity, are keen to review the data from this trial.

I also refer you to:

The directors believe that such a product could be very successful with annual revenues exceeding $1 billion, just for COPD, with further potential in other patient groups where these normally benign viruses cause serious illness.

Whilst some try and paint SNG001 as a high risk Covid19 only drug. I refer you to this comment on our COPD Phase 2 test:

Post period-end, as announced in July, a review of the blinded patient symptom data
using the Breathlessness Cough and Sputum Score (BCSS score) for the first 40
patients showed that the patients in the trial are being adversely affected by the
viruses. A change in the BCSS score of 1 or more is considered to be clinically
1
As we are seeing an average increase in BCSS score of more than 2, there
relevant.
is clearly an opportunity for inhaled IFN-beta to reduce symptom severity and show clinical benefit.

Formul1187
As I am accused of ramping and adding no value I thought I would ask you a question. Would you want to be out of this over the weekend ?

Whilst it is quiet I have skimmed through all Nolupus posts and boy there are so many. The majority have a negative slant to them, which is strange if they were invested into SNG.

As for your latest comment below. The majority of my research comes from either the CEO or Chairman at Synairgen or people allot more intelligent than you or I.
Anyhow back on filter. Ghai if I have wrongly accused you I apologise. I would ask you to stop encouraging our resident troll.
Sharesting,

You're such an open minded person , keep embarrassing yourself with your theories :-)

There are many many trials across the world using Interferon as a stand alone or combo treatment.
Everyone I have reviewed have seen a benefit.

So combine the above with the COPD trials (large % of Corona deaths are people with COPD) I believe we will see a positive outcome in June. The key question is what %, will it be high enough to proceed with the drug application whilst accelerating usage trials globally.

As I keep reminding everyone, we were already in discussions with “major pharmaceutical companies” about SNG001 pre Covid19.

Think so. I have emailed Admin to check. They are normally pretty quick to check.

I think Ghai and Noplus are the same person with dual
Accounts. Time to report them both and let LSE admin decide.

Anyone just focusing on SNG001 as a treatment only for Covid19 is either mistaken, under researched or a subtle troll.

I refer to my earlier comments quoting the Chairman of Synairgen on the COPD trials and Asthma trials. Pre Covid19, Synairgen has also identified 4 other areas where SNG001 could add value.

Synairgen were already in discussions with MAJOR pharmaceutical companies before Covid19.

This is no one trick pony.

Dave there is allot we don’t know about !
Look at the press the other weekend and Panorama coverage. Most companies would have leaked this. Not Synairgen. They are one tight ship.

Synairgen already have an outstanding global reputation. Look at the Chairman’s comments back in Sept19.

Warrenbe nice to see Synairgen on the Forbes list.. there are some real giants there.

Dave
How do you know Synairgen is one of the eight. I can’t see that anywhere ?
Thanks for clarification!

John you are so right and your comments are reflected in Synairgen’s last financial update where the Chairman comments on the COPD trials and they have a number of major pharmaceutical companies very interested.

Overlay then with now and you can start to see the size of the opportunity here. Did you see COPD was up there in total Covid19 deaths... on BBC and Sky News... this evening.

At under £100m this company is very undervalued (setting aside Covid19).

I like others will be holding to results and beyond.

Maqs can’t believe the resident troll is still spamming this board. I have it on filter. No facts just waffle. The ultimate troll.